Zang Jian, Li Chen, Zhao Li-Na, Wang Jian-Hua, Xu Man, Luo Shan-Quan, Hitchcock Ying J, Shi Mei
From the Department of Radiation Oncology (JZ, L-NZ, j-HW, MX, S-QL, MS), XiJing Hospital; Department of Health Statistics (CL), Faculty of Preventive Medicine, Fourth Military Medical University, Xi'an, Shanxi, China; and Department of Radiation Oncology (YJH), Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT.
Medicine (Baltimore). 2016 May;95(21):e3794. doi: 10.1097/MD.0000000000003794.
Few studies were conducted to explore the prognostic factors for nonendemic nasopharyngeal carcinoma (NPC) in the era of 3-dimensional conformal radiation therapy (3DCRT)/intensity-modulated radiation therapy (IMRT). The aim of this study was to evaluate the potential prognostic factors for nonendemic NPC.Between January 2004 and December 2011, a total of 393 nonendemic NPC patients receiving 3DCRT/IMRT were reviewed according to the inclusion and exclusion criteria. The prognostic factors we analyzed included age, T stage, N stage, lymph node diameter, primary tumor volume, WHO histology types, and cranial nerve related symptoms. All patients were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) system. The factors found to be associated with the endpoints by univariate analyses were then entered into multivariate Cox proportional hazards regression analysis.The median follow-up time was 61.4 months (range: 4-130 months). The 5-year local recurrent-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis free survival (DMFS), and disease-specific survival (DSS) for all patients were 89.3%, 96.4%, 73.5%, and 74.3%, respectively. Multivariate analysis indicated that N stage (N2-3), WHO pathologic type II, and primary tumor volume (>23 mL) were 3 independent prognostic factors for DSS and DMFS. According to the number of prognostic factors, patients were divided into 3 risk groups: low-risk group (patients without any risk factors); intermediate-risk group (patients with only 1 risk factor); and high-risk group (patients with more than 2 risk factors). The 5-year DSS for low, intermediate, and high-risk groups were 91.5%, 75.2%, and 49.3%, respectively (P < 0.001). The 5-year DMFS for low, intermediate, and high-risk groups were 89.4%, 77.9%, and 49.4%, respectively (P < 0.001).Advanced N stage (N2-3), larger tumor volume (>23 mL), and histological WHO type II are independently prognostic factors for nonendemic NPC patients in China.
在三维适形放射治疗(3DCRT)/调强放射治疗(IMRT)时代,很少有研究探索非地方性鼻咽癌(NPC)的预后因素。本研究的目的是评估非地方性NPC的潜在预后因素。
2004年1月至2011年12月期间,根据纳入和排除标准,对393例接受3DCRT/IMRT的非地方性NPC患者进行了回顾性分析。我们分析的预后因素包括年龄、T分期、N分期、淋巴结直径、原发肿瘤体积、世界卫生组织(WHO)组织学类型以及与脑神经相关的症状。所有患者均按照美国癌症联合委员会(AJCC)第7版系统进行分期。然后将单因素分析中发现与终点相关的因素纳入多因素Cox比例风险回归分析。
中位随访时间为61.4个月(范围:4 - 130个月)。所有患者的5年局部无复发生存率(LRFS)、区域淋巴结无复发生存率(NRFS)、远处转移无复发生存率(DMFS)和疾病特异性生存率(DSS)分别为89.3%、96.4%、73.5%和74.3%。多因素分析表明N分期(N2 - 3)、WHO病理类型II和原发肿瘤体积(>23 mL)是DSS和DMFS的3个独立预后因素。根据预后因素的数量,将患者分为3个风险组:低风险组(无任何风险因素的患者);中风险组(仅有1个风险因素的患者);高风险组(有2个以上风险因素的患者)。低、中、高风险组的5年DSS分别为91.5%、75.2%和49.3%(P < 0.001)。低、中、高风险组的5年DMFS分别为89.4%、77.9%和49.4%(P < 0.001)。
在中国,晚期N分期(N2 - 3)、较大的肿瘤体积(>23 mL)和WHO组织学类型II是非地方性NPC患者的独立预后因素。